JCM, Vol. 12, Pages 2912: The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome

JCM, Vol. 12, Pages 2912: The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome

Journal of Clinical Medicine doi: 10.3390/jcm12082912

Authors: Iason Psilopatis Kleio Vrettou Eleni Nousiopoulou Kostas Palamaris Stamatios Theocharis

Polycystic ovary syndrome (PCOS) constitutes the most common endocrine disorder in women of reproductive age. Patients usually suffer from severe menstrual irregularities, skin conditions, and insulin resistance-associated health conditions. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor proteins that regulate gene expression. In order to investigate the role of PPARs in the pathophysiology of PCOS, we conducted a literature review using the MEDLINE and LIVIVO databases and were able to identify 74 relevant studies published between 2003 and 2023. Different study groups reached contradictory conclusions in terms of PPAR expression in PCOS. Interestingly, numerous natural agents were found to represent a novel, potent anti-PCOS treatment alternatives. In conclusion, PPARs seem to play a significant role in PCOS.